Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes

This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.

Study Overview

• Status: Completed
• Conditions: Diabetic Macular Edema; Retinal Vein Occlusion; Wet Age Related Macular Degeneration; Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
• Intervention / Treatment: Drug: Ranibizumab; Other: Ranibizumab

• Study Type: Observational
• Enrollment (Actual): 30490

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina
    • Novartis Investigative Site
  • Buenos Aires, Argentina, 1121
    • Novartis Investigative Site
  • Buenos Aires, Argentina, Argentina
    • Novartis Investigative Site
  • Buenos Aires, Argentina, CP1425
    • Novartis Investigative Site
  • Caballito, Argentina, C1437AVJ
    • Novartis Investigative Site
  • Ciudad de Buenos Aires,, Argentina, Argentina
    • Novartis Investigative Site
  • Concepción del Uruguay, Argentina
    • Novartis Investigative Site
  • Córdoba, Argentina, CP 5000
    • Novartis Investigative Site
  • Guaymallén, Mendoza, Argentina
    • Novartis Investigative Site
  • La Plata, Argentina
    • Novartis Investigative Site
  • Rosario, Argentina
    • Novartis Investigative Site
  • San Martin, Buenos Aires, Argentina
    • Novartis Investigative Site
  • Santa Fe, Argentina, Argentina
    • Novartis Investigative Site
  • Santa Fe, Argentina
    • Novartis Investigative Site
  • Buenos Aires
    • Lanus, Buenos Aires, Argentina, B1824ABE
      • Novartis Investigative Site
    • Mar del Plata, Buenos Aires, Argentina
      • Novartis Investigative Site
  • Santa Fe
    • Rosario, Santa Fe, Argentina
      • Novartis Investigative Site
• Australia
  • New South Wales
    • Chatswood, New South Wales, Australia, 2067
      • Novartis Investigative Site
    • Forster, New South Wales, Australia, 2428
      • Novartis Investigative Site
    • Kogarah, New South Wales, Australia, 2217
      • Novartis Investigative Site
    • Liverpool, New South Wales, Australia, 2170
      • Novartis Investigative Site
    • North Ryde, New South Wales, Australia, 2109
      • Novartis Investigative Site
    • Parramatta, New South Wales, Australia, 2150
      • Novartis Investigative Site
    • Strathfield, New South Wales, Australia, 2135
      • Novartis Investigative Site
    • Sydney, New South Wales, Australia, 2000
      • Novartis Investigative Site
    • Sydney, New South Wales, Australia, Australia
      • Novartis Investigative Site
    • Westmead, New South Wales, Australia, 2145
      • Novartis Investigative Site
  • Queensland
    • Brisbane, Queensland, Australia, 4000
      • Novartis Investigative Site
    • South Brisbane, Queensland, Australia, 4101
      • Novartis Investigative Site
    • Southport, Queensland, Australia, 4125
      • Novartis Investigative Site
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • Novartis Investigative Site
    • North Adelaide, South Australia, Australia, 5006
      • Novartis Investigative Site
  • Tasmania
    • Hobart, Tasmania, Australia, 7000
      • Novartis Investigative Site
    • South Launceston, Tasmania, Australia, 7249
      • Novartis Investigative Site
  • Victoria
    • East Melbourne, Victoria, Australia, 3002
      • Novartis Investigative Site
    • Geelong, Victoria, Australia, 3220
      • Novartis Investigative Site
    • Glen Waverley, Victoria, Australia, VIC 3150
      • Novartis Investigative Site
    • Oakleigh, Victoria, Australia, 3166
      • Novartis Investigative Site
• Austria
  • Linz, Austria, A-4020
    • Novartis Investigative Site
  • Vienna, Austria, A 1040
    • Novartis Investigative Site
• Belgium
  • Aalst, Belgium, 9300
    • Novartis Investigative Site
  • Aarschot, Belgium, 3200
    • Novartis Investigative Site
  • Bonheiden, Belgium, 2820
    • Novartis Investigative Site
  • Bruxelles, Belgium, 1070
    • Novartis Investigative Site
  • Dinant, Belgium, 5500
    • Novartis Investigative Site
  • Edegem, Belgium, 2650
    • Novartis Investigative Site
  • Gent, Belgium, 9000
    • Novartis Investigative Site
  • Hasselt, Belgium, 3500
    • Novartis Investigative Site
  • Leuven, Belgium, 3000
    • Novartis Investigative Site
  • Mouscron, Belgium, 7700
    • Novartis Investigative Site
  • Namur, Belgium, 5000
    • Novartis Investigative Site
  • Nivelles, Belgium, 1400
    • Novartis Investigative Site
  • Reet, Belgium, 2840
    • Novartis Investigative Site
  • Yvoir, Belgium, 5530
    • Novartis Investigative Site
  • Zottegem, Belgium, 9620
    • Novartis Investigative Site
• Brazil
  • GO
    • Goiania, GO, Brazil, 74210-010
      • Novartis Investigative Site
  • MG
    • Belo Horizonte, MG, Brazil, 30150-270
      • Novartis Investigative Site
  • RJ
    • Rio de Janeiro, RJ, Brazil
      • Novartis Investigative Site
  • RS
    • Porto Alegre, RS, Brazil
      • Novartis Investigative Site
  • SP
    • Campinas, SP, Brazil, 13092-132
      • Novartis Investigative Site
    • São Paulo, SP, Brazil, 01501-000
      • Novartis Investigative Site
• Canada
  • Barrie, Canada, ON L4M 4S
    • Novartis Investigative Site
  • Drummondville, Canada, J2B 5L4
    • Novartis Investigative Site
  • Hamilton, Canada, L9C 5R3
    • Novartis Investigative Site
  • Ontario, Canada, M1E 4A7
    • Novartis Investigative Site
  • Alberta
    • Calgary, Alberta, Canada, T2H0C8
      • Novartis Investigative Site
  • British Columbia
    • Victoria, British Columbia, Canada, V8V 4X3
      • Novartis Investigative Site
  • New Brunswick
    • Miramichi, New Brunswick, Canada, E1V 1N9
      • Novartis Investigative Site
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 2A5
      • Novartis Investigative Site
  • Ontario
    • Brampton, Ontario, Canada, L6Y 0P6
      • Novartis Investigative Site
    • Downsview, Ontario, Canada, M5N 2V6
      • Novartis Investigative Site
    • East Brockville, Ontario, Canada, K6V 0V6
      • Novartis Investigative Site
    • London, Ontario, Canada, N6A 4G5
      • Novartis Investigative Site
    • Ottawa, Ontario, Canada, K1H 8L6
      • Novartis Investigative Site
    • Ottawa, Ontario, Canada, K1Z 8R2
      • Novartis Investigative Site
    • Scarborough, Ontario, Canada, M1R 3A6
      • Novartis Investigative Site
    • Toronto, Ontario, Canada, M5T 2S8
      • Novartis Investigative Site
    • Vaughan, Ontario, Canada, L4K 0C5
      • Novartis Investigative Site
  • Quebec
    • Boisbriand, Quebec, Canada, J7H 1S6
      • Novartis Investigative Site
• Chile
  • Calama, Chile
    • Novartis Investigative Site
• China
  • Beijing, China, 100730
    • Novartis Investigative Site
  • Beijing, China, 100034
    • Novartis Investigative Site
  • Beijing, China
    • Novartis Investigative Site
  • Changchun City, China, 130041
    • Novartis Investigative Site
  • Chongqing, China, 400038
    • Novartis Investigative Site
  • Fujian, China, 361001
    • Novartis Investigative Site
  • Shanghai, China, 200080
    • Novartis Investigative Site
  • Shanghai, China
    • Novartis Investigative Site
  • Shanghai, China, 200092
    • Novartis Investigative Site
  • Wulumuqi City, China, 830000
    • Novartis Investigative Site
  • Beijing
    • Beijing, Beijing, China, 100730
      • Novartis Investigative Site
    • Beijing, Beijing, China
      • Novartis Investigative Site
    • Beijing, Beijing, China, 100083
      • Novartis Investigative Site
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Novartis Investigative Site
  • Guizhou
    • Guiyang, Guizhou, China, 550004
      • Novartis Investigative Site
  • Hubei
    • Wuhan, Hubei, China, 430060
      • Novartis Investigative Site
  • Shandong
    • Jinan, Shandong, China, 250001
      • Novartis Investigative Site
  • Tianjin
    • Tianjin, Tianjin, China, 300020
      • Novartis Investigative Site
  • Yunnan
    • Kunming City, Yunnan, China, 650021
      • Novartis Investigative Site
• Colombia
  • Bogota, Colombia
    • Novartis Investigative Site
  • Bogotá, Colombia
    • Novartis Investigative Site
  • Cali, Colombia
    • Novartis Investigative Site
  • Yopal, Colombia
    • Novartis Investigative Site
  • Atlantico
    • Barranquilla, Atlantico, Colombia
      • Novartis Investigative Site
  • Quindío
    • Armenia, Quindío, Colombia
      • Novartis Investigative Site
• Costa Rica
  • San Jose, Costa Rica
    • Novartis Investigative Site
• Czech Republic
  • Brno - Bohunice, Czech Republic, 625 00
    • Novartis Investigative Site
  • Hradec Kralove, Czech Republic, 500 05
    • Novartis Investigative Site
  • Olomouc, Czech Republic, 775 20
    • Novartis Investigative Site
  • Ostrava-Poruba, Czech Republic, 708 52
    • Novartis Investigative Site
  • Plzen, Czech Republic, 304 60
    • Novartis Investigative Site
  • Praha, Czech Republic, 12808
    • Novartis Investigative Site
  • Praha, Czech Republic, 16902
    • Novartis Investigative Site
  • Praha 10, Czech Republic, 100 34
    • Novartis Investigative Site
  • Ustri nad Labem, Czech Republic, 401 13
    • Novartis Investigative Site
• Dominican Republic
  • Republica Dominicana
    • Santo Domingo, Republica Dominicana, Dominican Republic
      • Novartis Investigative Site
• Ecuador
  • Guayaquil
    • Ciudadela Kennedy, Guayaquil, Ecuador
      • Novartis Investigative Site
• Egypt
  • Cairo, Egypt
    • Novartis Investigative Site
  • Giza, Egypt
    • Novartis Investigative Site
• France
  • Bordeaux, France, 33 000
    • Novartis Investigative Site
  • Creteil, France, 94000
    • Novartis Investigative Site
  • Dijon, France, 21034
    • Novartis Investigative Site
  • Lyon CEDEX 04, France, 69317
    • Novartis Investigative Site
  • Melun, France, 77000
    • Novartis Investigative Site
  • Montargis, France, 45200
    • Novartis Investigative Site
  • Montauban, France, 82000
    • Novartis Investigative Site
  • Nantes Cedex 1, France, 44093
    • Novartis Investigative Site
  • Nice, France, 06200
    • Novartis Investigative Site
  • Paris, France, 75006
    • Novartis Investigative Site
  • Paris, France, 75015
    • Novartis Investigative Site
  • Paris Cedex 19, France, 75940
    • Novartis Investigative Site
  • Paris cedex 10, France, 75010
    • Novartis Investigative Site
  • Poitiers, France, 86000
    • Novartis Investigative Site
  • Reims, France, 51100
    • Novartis Investigative Site
  • Toulouse Cedex 9, France, 31059
    • Novartis Investigative Site
  • Vannes, France, 56000
    • Novartis Investigative Site
• Germany
  • Augsburg, Germany, 86156
    • Novartis Investigative Site
  • Berlin, Germany, 10367
    • Novartis Investigative Site
  • Berlin, Germany, 10707
    • Novartis Investigative Site
  • Bonn, Germany, D-53105
    • Novartis Investigative Site
  • Dannenberg, Germany, 29451
    • Novartis Investigative Site
  • Hamburg, Germany, 22587
    • Novartis Investigative Site
  • Ingolstadt, Germany, 85049
    • Novartis Investigative Site
  • Koeln, Germany, 50924
    • Novartis Investigative Site
  • Luedenscheid, Germany, 58515
    • Novartis Investigative Site
  • Muenster, Germany, 48149
    • Novartis Investigative Site
  • Muenster, Germany, 48145
    • Novartis Investigative Site
  • Neu-Ulm, Germany, 89231
    • Novartis Investigative Site
  • Osnabrück, Germany, 49076
    • Novartis Investigative Site
  • Regensburg, Germany, 93 047
    • Novartis Investigative Site
  • Rothenburg, Germany, 91541
    • Novartis Investigative Site
  • Schriesheim, Germany, 69198
    • Novartis Investigative Site
  • Tuebingen, Germany, 72076
    • Novartis Investigative Site
  • Tönisvorst, Germany, 47918
    • Novartis Investigative Site
• Greece
  • Alexandroupolis, Greece, 68100
    • Novartis Investigative Site
  • Athens, Greece, 11525
    • Novartis Investigative Site
  • Athens, Greece, 10436
    • Novartis Investigative Site
  • Athens, Greece, 176 73
    • Novartis Investigative Site
  • Lamia, Phthiotis, Greece, 35100
    • Novartis Investigative Site
  • GR
    • Athens, GR, Greece, 106 72
      • Novartis Investigative Site
    • Heraklion - Crete, GR, Greece, 711 10
      • Novartis Investigative Site
    • Larissa, GR, Greece, 411 10
      • Novartis Investigative Site
    • Patra - RIO, GR, Greece, 265 04
      • Novartis Investigative Site
    • Rethymno, GR, Greece, 741 00
      • Novartis Investigative Site
    • Thessaloniki, GR, Greece, 546 29
      • Novartis Investigative Site
• Guatemala
  • Guatemala City, Guatemala, 01010
    • Novartis Investigative Site
• Hong Kong
  • Kowloon, Hong Kong
    • Novartis Investigative Site
• Hungary
  • Budapest, Hungary, H-1083
    • Novartis Investigative Site
  • Budapest, Hungary, 1133
    • Novartis Investigative Site
  • Debrecen, Hungary, 4012
    • Novartis Investigative Site
  • Pecs, Hungary, 7624
    • Novartis Investigative Site
  • Szeged, Hungary, 6720
    • Novartis Investigative Site
• India
  • Ahmedabad, India, 380009
    • Novartis Investigative Site
  • New Delhi, India, 110 029
    • Novartis Investigative Site
  • Bhudaneswar
    • Patia, Bhudaneswar, India, 751 024
      • Novartis Investigative Site
  • Tamil Nadu
    • Chennai, Tamil Nadu, India, 600 006
      • Novartis Investigative Site
    • Coimbatore, Tamil Nadu, India, 641 014
      • Novartis Investigative Site
  • Telangana
    • Hyderabad, Telangana, India, 500 034
      • Novartis Investigative Site
• Ireland
  • Dublin, Ireland, 18
    • Novartis Investigative Site
  • Dublin 7, Ireland
    • Novartis Investigative Site
  • Waterford, Ireland
    • Novartis Investigative Site
• Israel
  • Haifa, Israel, 3339419
    • Novartis Investigative Site
  • Petach Tikva, Israel, 49100
    • Novartis Investigative Site
  • Tel Aviv, Israel, 64239
    • Novartis Investigative Site
• Italy
  • Alessandria, Italy
    • Novartis Investigative Site
  • Belluno, Italy, 32100
    • Novartis Investigative Site
  • Brescia, Italy, 25123
    • Novartis Investigative Site
  • Pisa, Italy, 56124
    • Novartis Investigative Site
  • Reggio Calabria, Italy, 89100
    • Novartis Investigative Site
  • Roma, Italy, 00168
    • Novartis Investigative Site
  • Roma, Italy, 00161
    • Novartis Investigative Site
  • BA
    • Acquaviva delle Fonti, BA, Italy, 70021
      • Novartis Investigative Site
  • CA
    • Cagliari, CA, Italy, 09124
      • Novartis Investigative Site
  • GE
    • Genova, GE, Italy, 16132
      • Novartis Investigative Site
• Japan
  • Akita, Japan
    • Novartis Investigative Site
  • Aomori, Japan, 030-8553
    • Novartis Investigative Site
  • Chiyoda-ku, Japan, 101-0062
    • Novartis Investigative Site
  • Ehime, Japan
    • Novartis Investigative Site
  • Gifu, Japan
    • Novartis Investigative Site
  • Hamamatsu-shi, Japan, 430-0903
    • Novartis Investigative Site
  • Hokkaido, Japan, 080-0805
    • Novartis Investigative Site
  • Hokkaido, Japan
    • Novartis Investigative Site
  • Hyogo, Japan
    • Novartis Investigative Site
  • Ishikawa, Japan
    • Novartis Investigative Site
  • Kagoshima, Japan, 890-0046
    • Novartis Investigative Site
  • Kagoshima, Japan
    • Novartis Investigative Site
  • Kakogawa-shi, Japan, 675-8611
    • Novartis Investigative Site
  • Kanagawa, Japan
    • Novartis Investigative Site
  • Kawasaki-shi, Japan, 211-0053
    • Novartis Investigative Site
  • Kitami-shi, Japan, 090-8666
    • Novartis Investigative Site
  • Koriyama-shi, Japan, 963-8585
    • Novartis Investigative Site
  • Kouchi, Japan, 783-8505
    • Novartis Investigative Site
  • Kyoto-shi, Japan, 604-0837
    • Novartis Investigative Site
  • Miyagi, Japan, 980-8574
    • Novartis Investigative Site
  • Nagano, Japan
    • Novartis Investigative Site
  • Nagasaki-shi, Japan, 852-8511
    • Novartis Investigative Site
  • Nantan-shi, Japan, 629-0392
    • Novartis Investigative Site
  • Osaka, Japan
    • Novartis Investigative Site
  • Otsu-shi, Japan, 520-2192
    • Novartis Investigative Site
  • Saitama, Japan, 338-8553
    • Novartis Investigative Site
  • Saitama-ken, Japan, 336-0963
    • Novartis Investigative Site
  • Sanjo-shi, Japan, 955-0852
    • Novartis Investigative Site
  • Shizuoka, Japan, 422-8527
    • Novartis Investigative Site
  • Shizuoka-shi, Japan, 420-0841
    • Novartis Investigative Site
  • Shunan-shi, Japan, 745-0017
    • Novartis Investigative Site
  • Tochigi, Japan
    • Novartis Investigative Site
  • Tokyo, Japan
    • Novartis Investigative Site
  • Tokyo, Japan, 153-8515
    • Novartis Investigative Site
  • Toyama, Japan, 930-0194
    • Novartis Investigative Site
  • Toyohashi-shi, Japan, 441-8106
    • Novartis Investigative Site
  • Wakayama, Japan, 640-8558
    • Novartis Investigative Site
  • Yamagata, Japan, 990-9585
    • Novartis Investigative Site
  • Yamagata, Japan
    • Novartis Investigative Site
  • Aichi
    • Nagakute-city, Aichi, Japan, 480-1195
      • Novartis Investigative Site
    • Nagoya-City, Aichi, Japan
      • Novartis Investigative Site
    • Nagoya-city, Aichi, Japan, 467-8602
      • Novartis Investigative Site
    • Nagoya-city, Aichi, Japan, 462-0825
      • Novartis Investigative Site
    • Toyoake-city, Aichi, Japan, 470-1192
      • Novartis Investigative Site
  • Chiba
    • Sakura, Chiba, Japan, 285-8741
      • Novartis Investigative Site
  • Ehime
    • Matsuyama, Ehime, Japan, 790-8524
      • Novartis Investigative Site
  • Fukui
    • Yoshida-gun, Fukui, Japan, 910-1193
      • Novartis Investigative Site
  • Fukuoka
    • Fukuoka-city, Fukuoka, Japan, 814-0180
      • Novartis Investigative Site
    • Fukuoka-city, Fukuoka, Japan, 812-8582
      • Novartis Investigative Site
    • Kitakyushu-city, Fukuoka, Japan, 807-8556
      • Novartis Investigative Site
  • Fukushima
    • Fukushima-city, Fukushima, Japan, 960-1295
      • Novartis Investigative Site
  • Gunma
    • Maebashi-city, Gunma, Japan, 371-8511
      • Novartis Investigative Site
  • Hiroshima
    • Hiroshima-city, Hiroshima, Japan, 734-8551
      • Novartis Investigative Site
  • Hokkaido
    • Sapporo-city, Hokkaido, Japan, 060-8543
      • Novartis Investigative Site
  • Hokkido
    • Sapporo-city, Hokkido, Japan
      • Novartis Investigative Site
  • Hyogo
    • Amagasaki-city, Hyogo, Japan, 660-8550
      • Novartis Investigative Site
    • Kobe, Hyogo, Japan, 657-0068
      • Novartis Investigative Site
    • Nishinomiya, Hyogo, Japan, 663-8501
      • Novartis Investigative Site
  • Ibaraki
    • Inashiki-gun, Ibaraki, Japan, 300-0395
      • Novartis Investigative Site
    • Tsukuba-city, Ibaraki, Japan, 305-8576
      • Novartis Investigative Site
  • Ishikawa
    • Kanazawa-city, Ishikawa, Japan, 920-8641
      • Novartis Investigative Site
  • Kagawa
    • Kita-gun, Kagawa, Japan, 761-0793
      • Novartis Investigative Site
  • Kanagawa
    • Ashigarakami-gun, Kanagawa, Japan
      • Novartis Investigative Site
    • Yokohama-city, Kanagawa, Japan, 232-0024
      • Novartis Investigative Site
    • Yokosuka-city, Kanagawa, Japan, 238-8558
      • Novartis Investigative Site
  • Kangawa
    • Yokohama, Kangawa, Japan
      • Novartis Investigative Site
  • Kyoto
    • Kyoto-city, Kyoto, Japan, 606-8507
      • Novartis Investigative Site
  • Mie
    • Tsu-city, Mie, Japan, 514-8507
      • Novartis Investigative Site
  • Miyagi
    • Sendai, Miyagi, Japan, 981-8563
      • Novartis Investigative Site
  • Miyazaki
    • Miyazaki-city, Miyazaki, Japan, 889-1692
      • Novartis Investigative Site
  • Miyazakiken
    • Miyakonojo-City, Miyazakiken, Japan
      • Novartis Investigative Site
  • Nagano
    • Suwa, Nagano, Japan, 392-8510
      • Novartis Investigative Site
  • Nagasaki
    • Nagasaki-city, Nagasaki, Japan, 852-8501
      • Novartis Investigative Site
  • Nara
    • Kashihara-city, Nara, Japan, 634-8522
      • Novartis Investigative Site
  • Osaka
    • Hirakata-city, Osaka, Japan, 573-1191
      • Novartis Investigative Site
    • Osaka-city, Osaka, Japan, 545-8586
      • Novartis Investigative Site
    • OsakaSayama, Osaka, Japan, 589-8511
      • Novartis Investigative Site
  • Saitama
    • Saitama-city, Saitama, Japan, 330-8503
      • Novartis Investigative Site
  • Shizuoka
    • Hamamatsu-city, Shizuoka, Japan, 430-8558
      • Novartis Investigative Site
    • Izunokuni, Shizuoka, Japan, 410-2295
      • Novartis Investigative Site
  • Tochigi
    • Shimotsuka-gun, Tochigi, Japan, 321-0293
      • Novartis Investigative Site
  • Tokushima
    • Tokushima-city, Tokushima, Japan, 770-8503
      • Novartis Investigative Site
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 113-8431
      • Novartis Investigative Site
    • Chiyoda-ku, Tokyo, Japan, 101-8309
      • Novartis Investigative Site
    • Mitaka-city, Tokyo, Japan, 181-8611
      • Novartis Investigative Site
    • Nerima-ku, Tokyo, Japan
      • Novartis Investigative Site
    • Shinjuku-ku, Tokyo, Japan, 160-0023
      • Novartis Investigative Site
    • Shinjuku-ku, Tokyo, Japan, 162-8666
      • Novartis Investigative Site
    • Urayasu, Tokyo, Japan, 279-0021
      • Novartis Investigative Site
  • Toyama
    • Imizu-shi, Toyama, Japan, 939-0243
      • Novartis Investigative Site
  • Yamanashi
    • Chuo-city, Yamanashi, Japan, 409-3898
      • Novartis Investigative Site
• Korea, Republic of
  • Busan, Korea, Republic of, 612-896
    • Novartis Investigative Site
  • Daegu, Korea, Republic of, 705-703
    • Novartis Investigative Site
  • Pusan, Korea, Republic of, 602-739
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 120-752
    • Novartis Investigative Site
  • Seoul, Korea, Republic of
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 150-950
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 137-701
    • Novartis Investigative Site
  • Seoul, Korea, Republic of, 130-872
    • Novartis Investigative Site
  • Taegu, Korea, Republic of, 700 - 721
    • Novartis Investigative Site
  • Gyeonggi
    • Seongnam, Gyeonggi, Korea, Republic of, 13620
      • Novartis Investigative Site
  • Gyeonggi-do
    • Suwon, Gyeonggi-do, Korea, Republic of, 443-721
      • Novartis Investigative Site
  • Korea
    • Seoul, Korea, Korea, Republic of, 05505
      • Novartis Investigative Site
    • Seoul, Korea, Korea, Republic of, 110 744
      • Novartis Investigative Site
• Malaysia
  • Kuala Lumpur, Malaysia, 56000
    • Novartis Investigative Site
  • Kuala Lumpur, Malaysia, 50603
    • Novartis Investigative Site
  • Kuala Lumpur, Malaysia, 59200
    • Novartis Investigative Site
  • Selangor
    • Batu Caves, Selangor, Malaysia, 68100
      • Novartis Investigative Site
• Mexico
  • CP
    • Col. Lomas de Chapultepec, CP, Mexico, 11000
      • Novartis Investigative Site
  • Distrito Federal
    • Ciudad De Mexico, Distrito Federal, Mexico, 06800
      • Novartis Investigative Site
    • Ciudad De Mexico, Distrito Federal, Mexico, 06030
      • Novartis Investigative Site
  • Nuevo León
    • Monterray, Nuevo León, Mexico, 64710
      • Novartis Investigative Site
    • Monterrey, Nuevo León, Mexico, 64020
      • Novartis Investigative Site
  • Yucatán
    • Mérida, Yucatán, Mexico
      • Novartis Investigative Site
• Netherlands
  • Almere, Netherlands, 1315 RA
    • Novartis Investigative Site
  • Amsterdam, Netherlands, 1071NT
    • Novartis Investigative Site
  • Tilburg, Netherlands, 5022 GC
    • Novartis Investigative Site
• Panama
  • Panamá
    • Panama, Panamá, Panama
      • Novartis Investigative Site
    • Panama City, Panamá, Panama, 0819-12316
      • Novartis Investigative Site
• Peru
  • Lima, Peru, Lima 13
    • Novartis Investigative Site
  • Lima
    • San Borja, Lima, Peru, 41
      • Novartis Investigative Site
    • San Isidro, Lima, Peru, 27
      • Novartis Investigative Site
• Poland
  • Bydgoszcz, Poland, 85-681
    • Novartis Investigative Site
  • Chojnice, Poland, 89-600
    • Novartis Investigative Site
  • Chorzow, Poland, 40-064
    • Novartis Investigative Site
  • Gdansk, Poland, 80-147
    • Novartis Investigative Site
  • Gda¿sk, Poland, 80-402
    • Novartis Investigative Site
  • Kalisz, Poland, 62 800
    • Novartis Investigative Site
  • Kielce, Poland, 25-514
    • Novartis Investigative Site
  • Krakow, Poland, 31-826
    • Novartis Investigative Site
  • Lodz, Poland, 93 357
    • Novartis Investigative Site
  • Olsztyn, Poland, 10-424
    • Novartis Investigative Site
  • Poznan, Poland, 61-693
    • Novartis Investigative Site
  • Walbrzych, Poland, 58-300
    • Novartis Investigative Site
  • Warszawa, Poland, 02-097
    • Novartis Investigative Site
  • Warszawa, Poland, 04-141
    • Novartis Investigative Site
  • Wolomin, Poland, 05-200
    • Novartis Investigative Site
• Portugal
  • Aveiro, Portugal, 3814-501
    • Novartis Investigative Site
  • Coimbra, Portugal, 3000-354
    • Novartis Investigative Site
  • Coimbra, Portugal, 3030-163
    • Novartis Investigative Site
  • Leiria, Portugal, 2410-104
    • Novartis Investigative Site
  • Lisboa, Portugal, 1500
    • Novartis Investigative Site
  • Matosinhos, Portugal, 4454-509
    • Novartis Investigative Site
  • Santa Maria Da Feira, Portugal, 4520-211
    • Novartis Investigative Site
• Russian Federation
  • Cheboksary, Russian Federation, 428028
    • Novartis Investigative Site
  • Chelyabinsk, Russian Federation, 454000
    • Novartis Investigative Site
  • Chita, Russian Federation, 672038
    • Novartis Investigative Site
  • Irkutsk, Russian Federation, 664033
    • Novartis Investigative Site
  • Kazan, Russian Federation, 420012
    • Novartis Investigative Site
  • Khabarovsk, Russian Federation, 680033
    • Novartis Investigative Site
  • Krasnodar, Russian Federation, 350012
    • Novartis Investigative Site
  • Moscow, Russian Federation, 105229
    • Novartis Investigative Site
  • Moscow, Russian Federation, 119021
    • Novartis Investigative Site
  • Moscow, Russian Federation, 10562
    • Novartis Investigative Site
  • Novosibirsk, Russian Federation, 630096
    • Novartis Investigative Site
  • Penza, Russian Federation, 440026
    • Novartis Investigative Site
  • Saint Petersburg, Russian Federation, Russia
    • Novartis Investigative Site
  • Samara, Russian Federation, 443079
    • Novartis Investigative Site
  • Saratov, Russian Federation, 410028
    • Novartis Investigative Site
  • Surgut, Russian Federation, 121359
    • Novartis Investigative Site
  • Tambov, Russian Federation, 392000
    • Novartis Investigative Site
  • Tyumen, Russian Federation, 625048
    • Novartis Investigative Site
  • Ufa, Russian Federation, 450077
    • Novartis Investigative Site
  • Yakutsk, Russian Federation, 677000
    • Novartis Investigative Site
• Saudi Arabia
  • Riyadh, Saudi Arabia, 11426
    • Novartis Investigative Site
  • Riyadh, Saudi Arabia, 11462
    • Novartis Investigative Site
  • Riyadh, Saudi Arabia, 11662
    • Novartis Investigative Site
• Singapore
  • Singapore, Singapore, 119074
    • Novartis Investigative Site
  • Singapore, Singapore, 168751
    • Novartis Investigative Site
  • Singapore, Singapore, 248649
    • Novartis Investigative Site
• Slovakia
  • Bratislava, Slovakia, 851 07
    • Novartis Investigative Site
  • Bratislava, Slovakia, 813 69
    • Novartis Investigative Site
  • Bratislava, Slovakia, 833 01
    • Novartis Investigative Site
  • Ljubljana, Slovakia, 1000
    • Novartis Investigative Site
  • Nove Zamky, Slovakia, 940 34
    • Novartis Investigative Site
  • Poprad, Slovakia, 058 01
    • Novartis Investigative Site
  • Ruzomberok, Slovakia, 034 01
    • Novartis Investigative Site
  • Trencin, Slovakia, SK-91171
    • Novartis Investigative Site
  • Zilina, Slovakia, 01207
    • Novartis Investigative Site
  • Zvolen, Slovakia, 960 01
    • Novartis Investigative Site
  • Slovak Republic
    • Banksa Bystrica, Slovak Republic, Slovakia, 974 17
      • Novartis Investigative Site
    • Trebisov, Slovak Republic, Slovakia, 075 01
      • Novartis Investigative Site
• Slovenia
  • Celje, Slovenia, 3000
    • Novartis Investigative Site
  • Ljubljana, Slovenia, 1000
    • Novartis Investigative Site
  • Maribor, Slovenia, 2000
    • Novartis Investigative Site
  • Novo Mesto, Slovenia
    • Novartis Investigative Site
• Spain
  • Barcelona, Spain, 08025
    • Novartis Investigative Site
  • Burgos, Spain, 09006
    • Novartis Investigative Site
  • Granollers, Spain, 08402
    • Novartis Investigative Site
  • Madrid, Spain, 28041
    • Novartis Investigative Site
  • Madrid, Spain, 28040
    • Novartis Investigative Site
  • Madrid, Spain, 28008
    • Novartis Investigative Site
  • Madrid, Spain, 28010
    • Novartis Investigative Site
  • Madrid, Spain, 28805
    • Novartis Investigative Site
  • Murcia, Spain, 30003
    • Novartis Investigative Site
  • Zaragoza, Spain, 50009
    • Novartis Investigative Site
  • Andalucia
    • Malaga, Andalucia, Spain, 29010
      • Novartis Investigative Site
  • Castilla y Leon
    • Leon, Castilla y Leon, Spain, 24071
      • Novartis Investigative Site
    • Salamanca, Castilla y Leon, Spain, 32007
      • Novartis Investigative Site
    • Valladolid, Castilla y Leon, Spain, 47011
      • Novartis Investigative Site
  • Catalunya
    • Sant Cugat, Catalunya, Spain, 08190
      • Novartis Investigative Site
    • Tarragona, Catalunya, Spain, 43005
      • Novartis Investigative Site
  • Cataluña
    • Barcelona, Cataluña, Spain, 08025
      • Novartis Investigative Site
  • Comunidad Valenciana
    • Valencia, Comunidad Valenciana, Spain, 46026
      • Novartis Investigative Site
    • Valencia, Comunidad Valenciana, Spain, 46015
      • Novartis Investigative Site
  • Galicia
    • Lugo, Galicia, Spain, 27003
      • Novartis Investigative Site
  • Hospital La Rioja provincia
    • Logroño, Hospital La Rioja provincia, Spain, 26001
      • Novartis Investigative Site
• Turkey
  • Altindag / Ankara, Turkey, 06590
    • Novartis Investigative Site
  • Ankara, Turkey, 06100
    • Novartis Investigative Site
  • Ankara, Turkey, 06500
    • Novartis Investigative Site
  • Mecidiyekoy/Istanbul, Turkey, 34394
    • Novartis Investigative Site
• Ukraine
  • Dnipropetrovsk, Ukraine, 49027
    • Novartis Investigative Site
  • Kyev, Ukraine, 03065
    • Novartis Investigative Site
  • Lugansk, Ukraine, 91055
    • Novartis Investigative Site
  • Odesa, Ukraine
    • Novartis Investigative Site
• United Kingdom
  • Bedford, United Kingdom, MK429DJ
    • Novartis Investigative Site
  • Birmingham, United Kingdom, B18 7QU
    • Novartis Investigative Site
  • Bristol, United Kingdom, BS1 2LX
    • Novartis Investigative Site
  • Cardiff, United Kingdom, CF14 4XN
    • Novartis Investigative Site
  • Cheshire, United Kingdom, CW1 4QJ
    • Novartis Investigative Site
  • Colchester, United Kingdom, CO3 3NB
    • Novartis Investigative Site
  • Inverness, United Kingdom, IV2 3UJ
    • Novartis Investigative Site
  • Kent, United Kingdom, CT1 3NG
    • Novartis Investigative Site
  • Leeds, United Kingdom, LS9 7TF
    • Novartis Investigative Site
  • Liverpool, United Kingdom, L9 7AL
    • Novartis Investigative Site
  • London, United Kingdom, NW3 2QG
    • Novartis Investigative Site
  • London, United Kingdom, SE5 9RS
    • Novartis Investigative Site
  • London, United Kingdom, EC1V 2PD
    • Novartis Investigative Site
  • London, United Kingdom, NW1 5QH
    • Novartis Investigative Site
  • Maidstone, United Kingdom, ME16 9QQ
    • Novartis Investigative Site
  • Manchester, United Kingdom, M13 9WL
    • Novartis Investigative Site
  • Merseyside, United Kingdom, CH49 5PE
    • Novartis Investigative Site
  • Merseyside, United Kingdom, L7 8PX
    • Novartis Investigative Site
  • Middlesborough, United Kingdom, TS4 3BW
    • Novartis Investigative Site
  • Newport, United Kingdom, P030 5TG
    • Novartis Investigative Site
  • Portsmouth, United Kingdom, PO6 3LY
    • Novartis Investigative Site
  • Southend, United Kingdom, SS0 0RY
    • Novartis Investigative Site
  • Sunderland, United Kingdom, SR2 9HP
    • Novartis Investigative Site
  • Uxbridge, United Kingdom, UB8 3NN
    • Novartis Investigative Site
  • Wolverhampton, United Kingdom, WV10 0QP
    • Novartis Investigative Site
  • York, United Kingdom, YO31 8HE
    • Novartis Investigative Site
  • Cornwall
    • Truro, Cornwall, United Kingdom, TR1 3LJ
      • Novartis Investigative Site
  • County Durham
    • Durham, County Durham, United Kingdom, DH1 5TW
      • Novartis Investigative Site
  • Devon,
    • Torquay, Devon,, United Kingdom, TQ2 7AA
      • Novartis Investigative Site
  • England
    • Bolton, England, United Kingdom, BL4 0JR
      • Novartis Investigative Site
    • Solihull, England, United Kingdom, B91 2JL
      • Novartis Investigative Site
    • Southampton, England, United Kingdom, SO16 6YD
      • Novartis Investigative Site
    • Wakefield, England, United Kingdom, WF1 3JS
      • Novartis Investigative Site
  • Essex
    • Belfast, Essex, United Kingdom, BT12 6BA
      • Novartis Investigative Site
    • Romford, Essex, United Kingdom, RM7 0AG
      • Novartis Investigative Site
  • Gloucestershire
    • Cheltenham, Gloucestershire, United Kingdom, GL53 7AN
      • Novartis Investigative Site
  • Lancashire
    • Blackburn, Lancashire, United Kingdom, BB2 3HH
      • Novartis Investigative Site
    • Hull, Lancashire, United Kingdom, HU3 2JZ
      • Novartis Investigative Site
    • Leicester, Lancashire, United Kingdom, LE1 5WW
      • Novartis Investigative Site
  • London
    • Coventry, London, United Kingdom, CV2 2DX
      • Novartis Investigative Site
    • Derby, London, United Kingdom, DE22 3NE
      • Novartis Investigative Site
    • Leytonstone, London, United Kingdom, E11 1NR
      • Novartis Investigative Site
  • Oxfordshire
    • Oxford, Oxfordshire, United Kingdom, OX3 9DU
      • Novartis Investigative Site
  • South Yorkshire
    • Sheffield, South Yorkshire, United Kingdom, S10 2JF
      • Novartis Investigative Site
  • Staffordshire
    • Stoke-on-Trent, Staffordshire, United Kingdom, ST4 7LN
      • Novartis Investigative Site
  • Surrey
    • Frimley, Surrey, United Kingdom, GU16 7UJ
      • Novartis Investigative Site
    • Guildford, Surrey, United Kingdom, GU2 7XX
      • Novartis Investigative Site
  • UK
    • Worcester, UK, United Kingdom, WR5 1DD
      • Novartis Investigative Site
  • West Yorkshire
    • Bradford, West Yorkshire, United Kingdom, BD9 6RJ
      • Novartis Investigative Site
• Venezuela
  • Caracas, Venezuela
    • Novartis Investigative Site
  • Caracas, Piso 6, Ofic. 607, Venezuela
    • Novartis Investigative Site
  • Santa Paula, Venezuela
    • Novartis Investigative Site
  • Torre Venezuela, Piso 1, Venezuela
    • Novartis Investigative Site
  • Isla Margarita
    • Porlamar Local 02, Isla Margarita, Venezuela
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Outpatient ophthalmology Clinics

Description

Inclusion Criteria:

• Adult patients, within age limits as defined by local regulations and local product label, who have previously been treated with, who are currently being treated with or initiating treatment with ranibizumab for any approved indication included in the local product label
• Willing and able to provide informed written consent personally or by legal proxy

Exclusion Criteria:

• Simultaneous participation in a study that includes administration of any investigational drug or procedure
• Systemic or ocular treatment with any VEGF inhibitor other than ranibizumab in the 90 days prior to enrollment
• Other protocol-defined inclusion/exclusion criteria may apply

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Ranibizumab	Drug: Ranibizumab; Other: Ranibizumab

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Mean Visual Acuity (VA) and mean change in VA	3,6, and 12 months from the baseline visit, and annually thereafter
Incidence rate, relationship and severity of treatment emergent ocular and non-ocular adverse events	Defined time periods during study duration from FPFV until 30 days after LPLV
Mean visual acuity at quarterly intervals for the primary treated eye set	Quarterly intervals from baseline visit during study duration (5 years)

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)	From the time the patient signed the informed consent until 30 days after study discontinuation
Number of ranibizumab injections administered per patient, per eye, and per person-year	annually
"National Eye Institute Visual Functioning Questionnaire-25" change from baseline	annually
Overall number of ranibizumab injections, number of visits, time interval between injections, duration of treatment, number of re-treatment, and reasons for treatment termination	Over time during study duration (5 years)
Change from baseline in National Eye Institute Visual Function Questionnaire 25 composite and sub-scale scores	Over time during study duration (5 years)

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Publications and helpful links

General Publications

• Holz FG, Minnella AM, Tuli R, Yoganathan P, Parikh S, Hamilton R; LUMINOUS study group. Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study. PLoS One. 2020 Dec 30;15(12):e0244183. doi: 10.1371/journal.pone.0244183. eCollection 2020.
• Leys AM, Ramboer E, Favreau M, Denhaerynck K, MacDonald K, Abraham I, Brie H. Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study. Clin Ophthalmol. 2020 Jun 2;14:1473-1481. doi: 10.2147/OPTH.S242547. eCollection 2020.
• Pearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, Creuzot-Garcher C, Spital G, Sakamoto T, Dunger-Baldauf C, McAllister IL; all the LUMINOUS study investigators. Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study. PLoS One. 2020 Jun 18;15(6):e0234739. doi: 10.1371/journal.pone.0234739. eCollection 2020.
• Mitchell P, Sheidow TG, Farah ME, Mahmood S, Minnella AM, Eter N, Eldem B, Al-Dhibi H, Macfadden W, Parikh S, Dunger-Baldauf C, Mahgoub MM, Schmidt-Erfurth U; LUMINOUS study investigators. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naive patients with diabetic macular edema: Results from the real-world global LUMINOUS study. PLoS One. 2020 Jun 3;15(6):e0233595. doi: 10.1371/journal.pone.0233595. eCollection 2020.
• Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Mones J, Richard G, Bandello F; European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014 Sep;98(9):1144-67. doi: 10.1136/bjophthalmol-2014-305702.

Study record dates

Study Major Dates

• Study Start: March 1, 2011
• Primary Completion (ACTUAL): April 1, 2016
• Study Completion (ACTUAL): April 1, 2016

Study Registration Dates

• First Submitted: March 17, 2011
• First Submitted That Met QC Criteria: March 17, 2011
• First Posted (ESTIMATE): March 21, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): May 23, 2016
• Last Update Submitted That Met QC Criteria: May 20, 2016
• Last Verified: May 1, 2016

More Information

Terms related to this study

• Keywords: Ranibizumab; Diabetic Macular Edema; Age-related macular degeneration; Ophthalmology; Retinal Vein Occlusion; Ophthalmology, age-related macular degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, ranibizumab; LUMINOUS
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Nervous System Diseases; Eye Diseases; Retinal Degeneration; Retinal Diseases; Embolism and Thrombosis; Venous Thrombosis; Thrombosis; Optic Nerve Diseases; Cranial Nerve Diseases; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Edema; Papilledema; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Ranibizumab
• Other Study ID Numbers: CRFB002A2406